BeiGene (NASDAQ: BGNE)
Q2 2022 | Est. | Actual | Surprise | ||||
---|---|---|---|---|---|---|---|
EPS | (EXPECTED)2022-08-04 | ||||||
REV |
Q1 2022 | Est. | Actual | Surprise | ||||
---|---|---|---|---|---|---|---|
EPS | -4.730 | -4.240 | 0.4900 | ||||
REV | 288.280M | 306.626M | 18.346M |
Date | Analyst Firm | Analyst Name | Action | Rating | Action Price | Prior Price | Target |
---|
You can purchase shares of BeiGene (NASDAQ: BGNE) through any online brokerage.
Other companies in BeiGene’s space includes: Legend Biotech (NASDAQ:LEGN), Exact Sciences (NASDAQ:EXAS), Sarepta Therapeutics (NASDAQ:SRPT), Neurocrine Biosciences (NASDAQ:NBIX) and Ionis Pharmaceuticals (NASDAQ:IONS).
The latest price target for BeiGene (NASDAQ: BGNE) was reported by Morgan Stanley on Monday, May 9, 2022. The analyst firm set a price target for 300.00 expecting BGNE to rise to within 12 months (a possible 79.69% upside). 9 analyst firms have reported ratings in the last year.
The stock price for BeiGene (NASDAQ: BGNE) is $166.95 last updated July 1, 2022, 8:00 PM UTC.
There are no upcoming dividends for BeiGene.
BeiGene’s Q2 earnings are confirmed for Thursday, August 4, 2022.
There is no upcoming split for BeiGene.
BeiGene is in the Health Care sector and Biotechnology industry. They are listed on the NASDAQ.